Vaccine Adjuvants

Vaccinations have proven to be the single most effective tool to manage and prevent infectious diseases in humans. Adjuvants are critical components of vaccines and the key to a single shot vaccination strategy. Despite the extensive worldwide success of vaccines, new vaccine development has been limited by inadequate protective immune responses, the limited ability of neonates to respond, and the need for multiple dosing to raise a protective response. Our ABT Vaccine Adjuvant Peptide technology addresses these issues by enhancing the body’s response to a vaccine and ensures an appropriate immune response to maximize the immune protection gained through vaccination.

With substantial funding from the Grand Challenges in Global Health program, through the Gates Foundation, we developed peptide containing vaccine adjuvant formulations that induce a strong immune response, are compatible with established vaccine platforms and are safe, stable and cost effective. The key advantages of our peptide adjuvant formulations are their ability to induce a high antibody titer and generate protective immune responses against pertussis, RSV, Chlamydia, Flu as well as other model antigens. Moreover, they have been shown to enable the creation of single dose vaccines (e.g. pertussis) which eliminates the need for multiple dosing, likely improving vaccine uptake in the population.

Read our publications related to Vaccine Adjuvants here.